Eosinophilia

Pooled trial evidence supports expanding clinical use of two markers in escalating therapy

Helicobacter pylori exposure is linked to a reduced risk for eosinophilic oesophagitis, with an increased reduction in studies published after 2019, a meta-analysis shows.

Case study highlights risk beyond intestinal obstruction

Long-ignored patches of progressively hardening skin finally receive a rare diagnosis

In two phase III trials, the treatment reduced exacerbations and improved lung function

Benralizumab is a highly effective biologic for the management of severe eosinophil asthma.

Cats constantly licking and chewing because of a skin condition called feline allergic dermatitis may benefit from a new generic treatment approved by the U.S. Food and Drug Administration.

No new safety signals and steroid use appeared to be reduced, but questions remain.

Measuring esophageal distensibility can help define the severity of early scarring in the esophagus of children with eosinophilic esophagitis and guide care.

In phase 3 trials, patients showed clinically meaningful reductions in itchiness and skin lesions with dupilumab compared with placebo.

The incidence of schistosomiasis is increasing in Europe. Primary care physicians, who are patients' first point of contact with the healthcare system, must be able to recognize and treat the disease.

Dublin, May 06, 2022 (GLOBE NEWSWIRE) -- The "Global Blood Collection Devices Market Size, Share & Industry Trends Analysis Report By End User, By Product...

Doctors watched the shifting rash blanket his body in rare hyperinfection.

FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis If approved, Dupixent would be the...

Subgroup targeting may hold promise for biologic

Scientific Reports - The first occurrence of an avian-style respiratory infection in a non-avian dinosaur

Medscape Medical News

In the parasite vs. bear vs. human battle, the grizzly parasite comes out on top.

It is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis that specifically targets the interleukin (IL)-13 cytokine.

Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab (Nucala) in a head-to-head phase 3 trial of the two drugs.